BioAxone BioSciences Announces Patent Issued for Pharmaceutical Compositions of BA-210, a Rho Inhibitor for the Treatment of Spinal Cord Injury
Seeking Global Licensing Partner for Phase 3 Clinical Development and Commercialization; FDA has granted Orphan Drug Status and Fast Track designation BOSTON–(BUSINESS WIRE)–#RhoInhibitor—BioAxone BioSciences, Inc., a clinical stage biotechnology company committed to discovering and developing drugs for neurological conditions, today announced that a new patent has been issued for BA-210, a Phase 3-ready pro-regenerative drug … [Read more…]
